Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Assets (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Other Non-Current Assets of $888000.0 for Q1 2026, up 81.6% year-over-year from $489000.0 in Q1 2025, and down 42.19% quarter-over-quarter from $1.5 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $888000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 81.6% year-over-year to $888000.0; the TTM figure through Mar 2026 stood at $888000.0 (up 81.6% YoY), while the FY2025 annual figure was $1.5 million, up 206.59% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $888000.0, down from $1.5 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.5 million in Q1 2022, with the low at $489000.0 in Q1 2025.
- The 5-year median for Other Non-Current Assets is $982000.0 (2022), against an average of $983764.7.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets surged 154100.0% in 2022, then slumped 44.34% in 2024.
- Viridian Therapeutics, Inc.\DE's Other Non-Current Assets stood at $982000.0 in 2022, then slumped by 38.49% to $604000.0 in 2023, then retreated by 17.05% to $501000.0 in 2024, then surged by 206.59% to $1.5 million in 2025, then tumbled by 42.19% to $888000.0 in 2026.
- Business Quant data shows VRDN's Other Non-Current Assets at $888000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Mar 31, 2026 | 888,000.00 |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 506,000.00 |
| Mar 31, 2025 | 489,000.00 |
| Dec 31, 2024 | 501,000.00 |
| Sep 30, 2024 | 853,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Mar 31, 2024 | 555,000.00 |
| Dec 31, 2023 | 604,000.00 |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 982,000.00 |
| Dec 31, 2022 | 982,000.00 |
| Sep 30, 2022 | 1.15 Mn |
| Jun 30, 2022 | 1.51 Mn |
| Mar 31, 2022 | 1.54 Mn |
| Dec 31, 2021 | 1.49 Mn |
| Sep 30, 2021 | 1.46 Mn |